TY - JOUR
T1 - Improving progression-free and overall survival in patients with cancer
T2 - A potential role for bisphosphonates
AU - Lipton, Allan
N1 - Funding Information:
Financial support for medical editorial assistance was provided by Novartis. A Lipton has served as a consultant for Amgen and Novartis; received honoraria from Amgen, Novartis, and Genentech; received research funding from Novartis, Monogram Biosciences, and Oncogene Sciences; and given expert testimony for Novartis.
PY - 2011/4
Y1 - 2011/4
N2 - Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.
AB - Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.
UR - http://www.scopus.com/inward/record.url?scp=79952609241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952609241&partnerID=8YFLogxK
U2 - 10.1517/14656566.2011.538384
DO - 10.1517/14656566.2011.538384
M3 - Review article
C2 - 21247359
AN - SCOPUS:79952609241
SN - 1465-6566
VL - 12
SP - 749
EP - 762
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 5
ER -
